RxDoctor Payments Data

Molly Sokolowski, NP

Family · Oak Lawn, ILNPI 1881159499

Payments from drug & device makers

$959in general payments, 2019–2025

Across 38 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$317
  • Boehringer Ingelheim$173
  • Actelion Pharmaceuticals US, Inc.$136
  • Merck$64
  • Bridgebio Pharma, Inc.$62
  • Scpharmaceuticals Inc.$56
  • plus $152 from 5 others

What the payments were for

  • Food & beverage$959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$12,778
Medicare patients
109
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag28$643,323
JardianceEmpagliflozin63$44,602
EntrestoSacubitril/Valsartan44$42,143
Tadalafil23$41,536
EliquisApixaban22$28,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$20,302
FarxigaDapagliflozin Propanediol23$18,268
Torsemide136$3,628
Potassium Chloride87$1,999
Sildenafil Citrate19$1,491
Klor-Con M20Potassium Chloride30$689
Spironolactone100$653
Furosemide82$410
Metoprolol Succinate34$375
Digoxin15$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi$136$643,32328 claims
Boehringer IngelheimJardiance$173$44,60263 claims
AstraZenecaFarxiga$317$18,26823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,941 family providers in Illinois.

Other family in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →